Moderna stock slides nearly 6% as CEO flags pullback in Phase III vaccine trials
Moderna shares fell 5.8% to $48.88 by midday Friday after CEO Stephane Bancel said the company will halt funding for new late-stage vaccine trials due to U.S. regulatory pushback. Trading volume reached 10.9 million shares. Investors await Moderna’s Feb. 13 earnings for updates on spending and pipeline plans.